← Cancer trial database
Trial Spotlight
Non-small cell lung cancer

Phase 2 osimertinib EGFR inhibitor plus cyclosporine A calcineurin/NFAT inhibitor in EGFR-mutant NSCLC

Trial status

Currently Recruiting

Status as of

Got an update?
Trial ID
NCT07874490 on ClinicalTrials.gov
Cancer type
Non-Small Cell Lung Cancer (NSCLC)
Stage of research
Exploratory
Location
New York, NY
Published in
New in Oncology - Nov 12, 2026

NYU Langone Health’s OCEAN trial is a single-site, biomarker-enriched, randomized, open-label Phase 2 study testing whether adding cyclosporine A (CsA) can deepen responses to osimertinib in metastatic EGFR-mutant NSCLC (exon 19 deletion or L858R). All consented patients who are ctDNA-positive at baseline receive a 3-week osimertinib run-in; those with persistent ctDNA (“shedders”) are randomly assigned 1:1 to continue AstraZeneca’s osimertinib (an irreversible, mutant-selective EGFR tyrosine kinase inhibitor) alone versus osimertinib plus CsA (a calcineurin inhibitor that suppresses NFAT signaling; used clinically as an immunosuppressant). Serial plasma ctDNA is collected about every 3 weeks to track molecular clearance, with imaging performed per usual care. The scientific angle is the ctDNA-guided “run-in → randomize only molecular non-responders” design, aiming to intensify therapy only for early resistant disease signals rather than treating everyone up front. Today’s care for first-line metastatic EGFR exon19/L858R NSCLC is osimertinib monotherapy, osimertinib with platinum/pemetrexed, or amivantamab plus lazertinib, followed by chemotherapy and/or targeted options at progression.

More in non-small cell lung cancer

See all entries in non-small cell lung cancer →